New combo therapy shows promise for early lung cancer

NCT ID NCT03110978

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated Jun 18, 2026 · Updated 30 times

Summary

This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus immunotherapy. The goal is to see if the combination improves how long people stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States
MD Anderson West Houston

Houston, Texas, 77079, United States
MD Anderson in The Woodlands

Conroe, Texas, 77384, United States

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung atypical carcinoid tumor lung adenocarcinoma lung cancer lung large cell carcinoma lung neoplasm lung neuroendocrine neoplasm minimally invasive lung adenocarcinoma neuroendocrine carcinoma non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.